Kornimate/medical-research-clean huggingface dataset:
acceptance and commitment therapy in improving well-being in patients with stage iii-iv cancer and their partners

Conditions: Malignant Female Reproductive System Neoplasm; Malignant Hepatobiliary Neoplasm; Partner; Stage III Breast Cancer; Stage III Cervical Cancer; Stage III Colorectal Cancer; Stage III Lung Cancer; Stage III Prostate Cancer; Stage III Skin Melanoma; Stage III Uterine Corpus Cancer; Stage IIIA Breast Cancer; Stage IIIA Cervical Cancer; Stage IIIA Colorectal Cancer; Stage IIIA Lung Carcinoma; Stage IIIA Skin Melanoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Breast Cancer; Stage IIIB Cervical Cancer; Stage IIIB Colorectal Cancer; Stage IIIB Lung Carcinoma; Stage IIIB Skin Melanoma; Stage IIIB Uterine Corpus Cancer; Stage IIIC Breast Cancer; Stage IIIC Colorectal Cancer; Stage IIIC Skin Melanoma; Stage IIIC Uterine Corpus Cancer; Stage IV Breast Cancer; Stage IV Cervical Cancer; Stage IV Colorectal Cancer; Stage IV Lung Cancer; Stage IV Prostate Cancer; Stage IV Skin Melanoma; Stage IV Uterine Corpus Cancer; Stage IVA Cervical Cancer; Stage IVA Colorectal Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Cervical Cancer; Stage IVB Colorectal Cancer; Stage IVB Uterine Corpus Cancer

Summary: this pilot clinical trial studies how well acceptance and commitment therapy works in improving well-being in patients with stage iii-iv cancer and their partners. learning how to accept negative thoughts and feelings and how to live in the present without worrying about the future or past may improve coping skills in patients with stage iii-iv cancer and their partners.

primary objectives: i. to examine the feasibility and acceptability of couples' acceptance and commitment therapy (act) (c-act). ii. to collect pilot data on the impact of c-act on patients' and partners' anxiety, depression, and quality of life. outline: patients and their partners attend 6 weekly act sessions over 60-75 minutes. couples learn skills of acceptance, avoidance, awareness, values and committed action, mindfulness and values in relationships, and handling persistent worries and concerns. patients and their partners also do homework assignment after each session. after completion of the study, patients and their partners are followed up at 1 week.

Eligibility criteria:
inclusion criteria: * diagnosed with stage 3 or 4 breast, cervical, colorectal, endometrial, hepatobiliary, lung, melanoma, gynecological, prostate cancer in the past six months * married or cohabiting with a significant other of either gender for more than one year * at the time of recruitment, a life expectancy of greater than 6 months and/or a karnofsky performance status of 80 or above or an eastern cooperative oncology group (ecog) score of 0 or 1 * english speaking * no significant hearing impairment that would prevent participation in sessions * live within a 1 hour commuting distance from rutgers cancer institute of new jersey exclusion criteria: * partner cannot have cancer diagnosis (other than non-melanoma skin cancer) and be currently receiving treatment
ventilation associated pneumonia and covid-19

Conditions: SARS-CoV2 Infection; Ventilator Associated Pneumonia; Ards; COVID-19

Summary: in december 2019, a new pandemic emerged, the covid-19 disease caused by a sars-cov-2 virus. one of the most common symptoms of covid-19 is mainly respiratory failure and patients requires assistance by mechanical ventilation. ventilator-associated pneumonia (vap) is a risk of this assistance. since the beginning of the pandemic, standard of care have evolved with new data. the prevalence of these vaps seems significantly higher in the population of patients with ards covid-19 (40-50%) and their ecology seems to have evolved over time, particularly in terms of bacterial resistance. investigators want to describe and compare this evolution of bacterial and fungal ecology as well as identify potential risk factors that may be associated with these changes in ecology during different waves.


Eligibility criteria:
inclusion criteria: * age \> 18 years * positive sars-cov-2 polymerase chain reaction (pcr) * healthcare associated pneumonia exclusion criteria : patient opposition to participate to the study

Keywords: intensive care unit multidrug resistance covid 19 ards ventilator associated pneumonia sars-cov2 infection
the risk of exacerbation of chronic hepatitis b after percutaneous radiofrequency ablation of hepatocellular carcinoma

Conditions: Hepatitis B; Hepatocellular Carcinoma

Summary: this study aim to find out the risk of exacerbation of chronic hepatitis b after percutaneous radiofrequency ablation (rfa) or hepatectomy for hcc, and it's effect to treatment outcome.

it has been reported that hbv replication can be reacted after chemotherapy or immunotherapy, which will lead to exacerbation of chronic hepatitis b (echb). it is still unknown that if percutaneous radiofrequency ablation or liver resection for hepatocellular carcinoma (hcc) will react the replication of hbv or not. this study aim to find out the risk of exacerbation of chronic hepatitis b after percutaneous radiofrequency ablation (rfa) or hepatectomy for hcc, and it's effect to treatment outcome.

Eligibility criteria:
inclusion criteria: * age 18 - 75 years * hbv carrier with hcc * after percutaneous radiofrequency ablation; * no history of encephalopathy, ascites refractory to diuretics or variceal bleeding * no hcv or hiv co-infection * no previous treatment of hcc * no previous treatment of hbv except lamivudine exclusion criteria: * patient compliance is poor * active clinically serious infections ( \> grade 2 national cancer institute \[nci\]-common terminology criteria for adverse events \[ctcae\] version 3.0) * known history of human immunodeficiency virus (hiv) infection * known central nervous system tumors including metastatic brain disease * patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry * distantly extrahepatic metastasis * history of organ allograft * substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results * excluded therapies and medications, previous and concomitant * prior use of any systemic anti-cancer treatment for hcc, eg. chemotherapy, immunotherapy or hormonal therapy (except that hormonal therapy for supportive care is permitted). antiviral treatment is allowed, however interferon therapy must be stopped at least 4 weeks prior randomization * prior use of systemic investigational agents for hcc * autologous bone marrow transplant or stem cell rescue within four months of start of study drug

Keywords: hepatitis b hepatocellular carcinoma radiofrequency ablation reactivation
remote therapeutic monitoring exercise tracking

Conditions: Parkinson Disease; Multiple Sclerosis

Summary: the purpose of this study is to examine physical activity and exercise behaviors in people with parkinson's disease and multiple sclerosis over the course of 1-year using a cloud-based remote monitoring platform.

remote therapeutic monitoring (rtm) is a reimbursable clinical service. pilot investigation conducted by our lab demonstrated promise that this service is feasible to add to clinical care. it is unclear still if rtm is able to provide clinical benefit to patients including improving and sustaining physical activity (pa) and exercise behaviors over a longer period of time (\>1 year). our central hypothesis is that the addition of rtm to physical activity, both in a skilled rehabilitation program and within a home program, will improve long term outcomes related to physical activity including self-efficacy for exercise, consistent participation in home exercise recommendations, and quality of life in people living with pd and ms. thus the specific aims of this study are as follows: 1. to assess pa and exercise behaviors over 1-year period using a remote therapeutic monitoring platform a. we will track steps per day, minutes of aerobic activity per week, and frequency of workouts including flexibility, balance, and resistance training. 2. to understand how engagement with rtm for pa tracking affects overall self-efficacy for exercise, readiness for exercise behavior change, and quality of life. 1. assessed through monthly self-report of usability survey for rtm and self-efficacy for exercise survey.

Eligibility criteria:
inclusion criteria: * are ambulatory as their primary means of mobility without an assistive device except for single point cane or walking sticks in community * have a diagnosis of parkinson's disease (hoehn and yahr 1-3), parkinsonism, or multiple sclerosis * personal goal and willingness to address physical activity * have a smart phone (datos health app is compatible with any smart phone device) * willing to accept datos' terms and conditions exclusion criteria: * individuals with cognitive or communication disorders (including dementia) which would limit their ability to interact with the rtm

Keywords: physical activity exercise tracking remote therapeutic monitoring quality of life self-efficacy
proteogenomics for follicular cell-derived thyroid cancer: development of a classification and prognosis prediction model

Conditions: Thyroid Cancer

Summary: this study aims to refine the molecular classification of thyroid cancer (tc) using a multi-omics approach. by identifying a novel gene set and applying decision-tree modeling, the study seeks to improve diagnostic accuracy and predict tumor progression in brafv600e-like and ras-like tc subtypes. protein biomarkers were validated via immunohistochemistry (ihc), with findings confirmed across external datasets.


Eligibility criteria:
inclusion criteria: * patients with a confirmed clinical diagnosis of thyroid cancer * availability of surgically resected thyroid tissue suitable for omics analysis exclusion criteria: - patients who have received chemotherapy for other malignancies

Keywords: thyroid cancer proteogenomics
efficacy and safety study of telbivudine to prevent perinatal transmission

Conditions: Chronic Hepatitis B, Gestation

Summary: the purpose of this study is to evaluate the efficacy and safety of telbivudine in pregnancy for the prevention of hbv perinatal transmission in highly viraemic mothers.

in the present study, we evaluated the effect of telbivudine given during the second and third trimesters of pregnancy to highly viremic, hbv dna-positive mothers on maternal hbv dna and hbeag levels prior to delivery and the rate of vertical transmission of hbv to infants who received passive-active immunoprophylaxis. additionally, we investigated the timing of the administration of telbivudine on reducing the risk of perinatal transmission and the safety of telbivudine during pregnancy.

Eligibility criteria:
inclusion criteria: * 20-40 years old pregnant woman with gestational age of 20-32 week; * positive serum hbsag; * hbv dna≥1.0x106 copies/ml; exclusion criteria: * with previous antiviral treatment; * with clinical sign of threatened miscarriage or related treatment in early pregnancy; * positive serum hav, hcv, hdv and hev tests; * fetus deformity by 3-d ultrasound examination; * on other dugs, such as immune modulators, cytotoxic drugs or steroids; * husbands are infected with hbv.

Keywords: chronic hepatitis b, telbivudine, intrauterine transmission
comparison of antimicrobial coated ureteral stents with non-coated stents

Conditions: Quality of Life

Summary: this study will be conducted to compare the efficacy of antimicrobial coated ureteral stent with non-coated stents in prevention of uti in patients with ureteral stents

the efficacy of antimicrobial coated of ureteral stent with silver sulphadiazine in prevention of uti in patients with ureteral stents will be studied by comparining the results of urine and stent cultures with patients who had non-coated ureteral stents. the impact of antimicrobeal stent coating on patients' quality of life will be evaluated with comparing the scores of ureteral stent symptom questionnaire between both groups.

Eligibility criteria:
inclusion criteria: * patients who will undergo ureteral stent placement exclusion criteria: * patients allergic to sulpha containing medications * ureteral stent insertion for infected hydronephrosis * patients who developed septic complications requiring antibiotic treatment after stent placement * patients who need bilateral stents * patients with chronic kidney disease grade iv and v (gfr \<30ml/min) * immunocompromised patients as those with malignancy or organ transplantation.

Keywords: ureteral stents double j stent antimicoreal coated stent ussq uti
a long-term study of mometasone furoate in patients with perennial allergic rhinitis (study p04459)

Conditions: Perennial Allergic Rhinitis

Summary: this study examined the safety and effectiveness of long-term administration of mometasone nasal spray in patients with perennial allergic rhinitis. patients received mometasone for 12 weeks plus an additional 12 weeks if patient agreed to continue. dose of mometasone could be decreased or increased during the study based on patient's response.


Eligibility criteria:
inclusion criteria: * moderate to severe perennial allergic rhinitis, \>16 years of age exclusion criteria: * patients with coexisting tuberculous disease or lower respiratory tract infection and patients who have acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis judged by the investigator to require treatment * patients with coexisting infections or systemic mycosis for which there are no effective treatment * patients with coexisting mycosis in the nasal and paranasal cavities * patients who are judged to require prohibited concomitant drugs during the clinical study * patients who have experienced recent nasal septum ulcers, nasal surgery, or nasal trauma, which have not yet healed * patients with a history of hypersensitivity to steroids or mometasone furoate * patients who are pregnant or nursing or who may be pregnant and patients or whose partner desires to become pregnant during the study period * patients with severe hepatic disorder, renal disorder, cardiac disease, diabetes mellitus, hypertension, or hematological disease or other serious coexisting diseases and whose general condition is poor as judged by the investigators. * patients allergic to pollen and the pollen release season occurs in the 7 days before the start of treatment * patients diagnosed with vasomotor rhinitis or eosinophilic rhinitis * patients with nasal conditions which may interfere with efficacy evaluation of the study drug * patients who develop a disease which may affect nasal symptoms in the 7 days before the start of treatment * patients who are participating or have participated in a clinical trial of an investigational drug within 120 days before the day of obtaining informed consent * patients for whom the period of discontinuation of previous treatment before the start of study drug administration indicated table 2 is not adequate or who cannot avoid the use of these drugs * patients undergoing specific desensitization therapy or nonspecific allassotherapy (histaglobin, vaccine therapy, etc.) or who had discontinued such therapy within 90 days prior to obtaining informed consent. (however, patients need not be excluded if therapy has been ongoing for at least 180 days before obtaining informed consent and maintenance therapy is now being conducted.)
antimuscarinic treatment for female patients with overactive bladder syndrome: comparison of daytime and nighttime dosing

Conditions: Overactive Bladder Syndrome

Summary: the aim of this retrospective study is to analyze if nighttime antimuscarincs may be more effective in treating patients with nocturia.


Eligibility criteria:
inclusion criteria: * patients who underwent tolterodine sr treatment once per day for 12 weeks in department of obstetrics \& gynecology in national taiwan university hospital and far eastern memorial hospital exclusion criteria: -
timing carotid stent clinical study for the treatment of carotid artery stenosis（timing trial）

Conditions: Carotid Artery Diseases; Carotid Artery Stenosis; Stroke; Ischemic Stroke

Summary: evaluate the safety and efficacy of the timing carotid stent for the treatment of carotid artery stenosis in patients.

this is a prospective, randomized, concurrent controlled, multi-center study. patients with carotid artery stenosis will be assigned to either the timing carotid stent or carotid wallstent. each treated patient will be followed and assessed for 12 months after randomization. the hypothesis to be tested is that the safety and effectiveness of the timing carotid stent is not inferior to the carotid wallstent.

Eligibility criteria:
inclusion criteria: 1. aged 18-85 years; 2. patient is either symptomatic with carotid stenosis ≥50% or asymptomatic with carotid stenosis ≥70% ; 3. target lesion 3.5- 5.5 mm; 4. signed informed consent. exclusion criteria: 1. target lesion is not caused by atherosclerotic disease； 2. target lesion is located at the opening of the common carotid artery； 3. patient has severe lesion calcification that may restrict the full deployment of the carotid 4. patient has a total occlusion of the target carotid arteries 5. patient has a large number of acute or subacute thrombi and arteriovenous malformations near the target lesion 6. patient has a severe stenosis or occlusion in series with target lesions 7. patient has known severe carotid stenosis contralateral to the target lesion 8. patient need angioplasty in other parts (including intracranial and extracranial) at the same time or within 30 days after procedure 9. patient has a symptomatic severe stenosis of other blood vessels (including intracranial and extracranial) except carotid artery 10. patient is experiencing (or has experienced) an evolving, acute, or recent disabling stroke or intracranial hemorrhage 11. patient has a massive stroke or myocardial infarction 12. patient has a intracranial aneurysm 13. patient has a coagulation dysfunction or abnormal bleeding, or contraindications to heparin and antiplatelet drugs 14. patient has known sensitivity to contrast agent 15. patient has a platelet \< 90 × 109 / l, severe liver and kidney injury, and severe dysfunction of important organs such as heart, lung, liver and kidney 16. patient has a uncontrollable severe hyperemia 17. patient has a bradycardia 18. mrs≥3 19. patient has life expectancy of less than one year 20. patient is currently enrolled in another investigational study protocol 21. females who are pregnant or in lactation 22. other conditions not suitable for inclusion judged by the researcher -
dose escalation and expansion study of cm313 in subjects with relapsed or refractory multiple myeloma and lymphoma

Conditions: Multiple Myeloma; Lymphoma

Summary: this is a multi-center, open-label, dose escalation and dose expansion, phase 1 study to evaluate the safety, tolerability, pk and preliminary anti-tumor activity of cm313. the dose escalation part will determine the mtd of cm313 in subjects with relapsed and/or refractory multiple myeloma (rrmm) or lymphoma based on a modified 3+3 dose escalation design (an accelerated dose titration design followed by traditional 3+3 dose escalation design). the dose expansion part includes two cohorts. cohort 1 will evaluate the safety and preliminary anti-tumor activity of cm313 in combination with dexamethasone in subjects with rrmm. cohort 2 will evaluate the safety and preliminary anti-tumor activity of cm313 in combination with rd regimen (lenalidomide/dexamethasone) in subjects with rrmm or newly diagnosed mm (ndmm).


Eligibility criteria:
key inclusion criteria: * dose escalation: subjects with rrmm who have progressed on, or could not tolerate, all available established therapies and subjects with recurrent and refractory lymphoma. * dose expansion_cohort 1: subjects with rrmm who have progressed on, or could not tolerate, all available established therapies. * dose expansion_cohort 2: subjects with rrmm who have progressed on, or could not tolerate, all available established therapies, or subjects with ndmm. * for mm: documented initial diagnosis of multiple myeloma according to international myeloma working group (imwg) diagnostic criteria. * for mm: serum monoclonal paraprotein (m-protein) level greater than or equal to (\>=) 0.5 gram per deciliter (g/dl) or urine m-protein level \>=200 milligram per 24 hours (mg/24 h) or light chain multiple myeloma without measurable disease in the serum or the urine: serum immunoglobulin free light chain (flc) \>= 10 mg/dl and abnormal serum immunoglobulin kappa lambda flc ratio. * eastern cooperative oncology group (ecog) performance status score \<＝2. * women of childbearing potential and male subjects must agree to remain abstinent or use contraceptive methods as defined by the protocol. * side effects of any prior therapy or procedures for any medical condition has recovered to nci-ctcae v.5.0 grade ≤ 1. key exclusion criteria: * previous treatment with any anti-cd38 therapy. * subjects with concurrent plasma cell leukemia. * received a cumulative dose of corticosteroids equivalent to greater than or equal to ( \>=) 140 milligram (mg) of prednisone within the 14-day period before the first dose of study drug (does not include pretreatment medication). * vaccinated with live, attenuated vaccine within 4 weeks prior to the first dose. * received an allogenic stem cell transplant or an autologous stem cell transplant within 3 months before first dose of study drug. * central nervous system (cns) involvement. * the forced expiratory volume in one second (fev1)\<60%.
the use of iron therapy for patients with anemia after caesarean section

Conditions: Postoperative Anaemia

Summary: the purpose of this study is to determine whether oral or intravenous iron is effective in the treatment of anaemia (iron-poor blood) after caesarean section.

anemia after caesarean section is often treated with iron therapy to ensure that the hemoglobin will return to normal more rapidly. scientific evidence for this action is limited. several studies, in which iron therapy was given after orthopaedic or cardiac surgery, show that after 6 to 10 weeks the hemoglobin was not significantly different between patients treated with oral preparations and patients treated with a placebo. these studies have not examined the hemoglobin level during the first few weeks after surgery including the quality of life analysis. the purpose of this double blind randomized controlled trial therefore is to examine the effect of both oral iron therapy and intravenous iron therapy on hemoglobin level and on the quality of life during the first few weeks postcaesarean in patients with a moderate anemia.

Eligibility criteria:
inclusion criteria: * gynecological surgery * hb 5-7 mmol/l exclusion criteria: * pregnancy * oncological operations * infections (pid) * diagnostic procedures: level 1 laparoscopies (diagnostic, sterilization, tubal testing; hysteroscopies * smaller therapeutic procedures: large loop excision of transformation zone (lletz), conization, * small vulvar / vaginal operations such as (cysts, labia correction) * endometrial ablation * legal incapacity * the patient has used pre-operatively an iron preparation and / or blood transfusion or during the surgery * hematologic disorders * erythropoiesis-stimulating agents \&lt; 3months ago * myelosuppressive therapy in history * hepatitis * hiv * alcohol abuses * not understanding dutch * allergic reaction to iron therapy in past

Keywords: postoperative anemia gynaecologic surgery